The PNUTS-PP1 complex acts as an intrinsic barrier to herpesvirus KSHV gene expression and replication.

Our CEO, Peter Chu, reflects on the successes of the past year and looks forward to 2025 in this Thanksgiving-themed eBlog.

In this eBlog we discuss the mechanisms of siRNA off-target interactions and outlines strategies to minimize them.

RNA secondary structure is a key determinant of RNA biology and therapeutic efficacy. In this eBlog, we review how RNA structure affects the development of RNA vaccines, siRNAs, and ASOs.

SAN DIEGO, September 3, 2024 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in developing precision solutions for RNA-based and RNA-targeting therapeutics, today announced the launch of its eSENSE dsRNA™ assay. eSENSE dsRNA is a next-generation sequencing method for the robust quantification, localization, and optimization of double-stranded RNA (dsRNA) contaminants in RNA-based vaccines and therapeutics. “By […]